Drug Type Fc fusion protein |
Synonyms SL-366252, TIM3 x OX40L (Shattuck Labs/Takeda) |
Target |
Action agonists, inhibitors |
Mechanism OX40 agonists(Tumor necrosis factor receptor superfamily member 4 agonists), galectin-9 inhibitors(galectin 9 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Neoplasms | Preclinical | United States | 06 Nov 2018 |






